Biotie Therapies Oyj closed out the year exactly as planned – with a product undergoing regulatory review in Europe. Development partner H. Lundbeck A/S disclosed on Dec. 21 that the European Medicines Agency (EMA) had accepted for review its marketing authorization application (MAA) for nalmefene to treat alcohol dependence.